Costing implications of recent treatment interruption studies
AIDS
.
2006 Nov 14;20(17):2239-40.
doi: 10.1097/01.aids.0000252057.02187.73.
Authors
M John Gill
,
Hartmut B Krentz
PMID:
17086069
DOI:
10.1097/01.aids.0000252057.02187.73
No abstract available
Publication types
Letter
MeSH terms
Antiretroviral Therapy, Highly Active / economics*
CD4 Lymphocyte Count
Costs and Cost Analysis
Disease Progression
HIV Infections / drug therapy
HIV Infections / economics*
Humans
Withholding Treatment / economics